A detailed history of Lsv Asset Management transactions in Incyte Corp stock. As of the latest transaction made, Lsv Asset Management holds 2,923,410 shares of INCY stock, worth $222 Million. This represents 0.41% of its overall portfolio holdings.

Number of Shares
2,923,410
Previous 2,769,892 5.54%
Holding current value
$222 Million
Previous $168 Million 15.08%
% of portfolio
0.41%
Previous 0.37%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$57.33 - $68.61 $8.8 Million - $10.5 Million
153,518 Added 5.54%
2,923,410 $193 Million
Q2 2024

Aug 06, 2024

BUY
$51.18 - $63.75 $773,585 - $963,581
15,115 Added 0.55%
2,769,892 $168 Million
Q1 2024

May 06, 2024

BUY
$56.55 - $66.59 $3.56 Million - $4.19 Million
62,950 Added 2.34%
2,754,777 $157 Million
Q4 2023

Feb 06, 2024

BUY
$52.16 - $64.19 $76.5 Million - $94.1 Million
1,465,792 Added 119.56%
2,691,827 $169 Million
Q3 2023

Nov 03, 2023

BUY
$57.77 - $65.93 $2.72 Million - $3.11 Million
47,100 Added 4.0%
1,226,035 $70.8 Million
Q2 2023

Aug 02, 2023

SELL
$60.95 - $75.51 $804,540 - $996,732
-13,200 Reduced 1.11%
1,178,935 $73.4 Million
Q1 2023

May 02, 2023

SELL
$70.23 - $86.01 $456,495 - $559,065
-6,500 Reduced 0.54%
1,192,135 $86.2 Million
Q4 2022

Feb 08, 2023

BUY
$67.18 - $84.11 $8.44 Million - $10.6 Million
125,570 Added 11.7%
1,198,635 $96.3 Million
Q3 2022

Nov 07, 2022

BUY
$66.18 - $82.86 $70.1 Million - $87.8 Million
1,059,965 Added 8091.34%
1,073,065 $71.5 Million
Q2 2022

Aug 10, 2022

BUY
$66.18 - $83.18 $866,958 - $1.09 Million
13,100 New
13,100 $995,000

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $16.9B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Lsv Asset Management Portfolio

Follow Lsv Asset Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lsv Asset Management, based on Form 13F filings with the SEC.

News

Stay updated on Lsv Asset Management with notifications on news.